The protein therapeutics market totaled $63 billion in 2007 ($39 billion in the U.S. alone) and is expected to reach $87 billion by 2010, according to a report by Kalorama Information—“Protein ...

A problem for biopharmaceutical companies comes as degraded proteins lead to ineffective and possibly dangerous medicines for their clients. Drug companies work on formulation development to protect ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure With its high efficiency and simplified ...

Proteins are life's molecular workhorses, doing everything from turning sunlight into food to fighting viruses. They are built from 20 different types of amino acid molecules, so even a small protein ...

Non-ionic surfactants such as polysorbates and poloxamers play a crucial role in biopharmaceutical formulations, improving protein stability and reducing aggregation. Polysorbates, such as Polysorbate ...

A new storage technique can keep protein-based drugs and vaccines stable without keeping them cold. The discovery, led by researchers at Penn State, could eliminate the need for refrigeration for ...

Protein therapeutics like insulin and GLP-1 inhibitors have a problem. They tend to aggregate when heated or shaken, robbing them of their potency. Researchers have now developed a ...

Spray-dried protein microparticles without MoNi surfactant form paste-like materials (left), whereas those spray dried with MoNi surfactant form injectable suspensions that flow like liquids (right).

Non-invasive delivery systems, like needle-free nasal sprays, improve patient adherence by addressing psychological barriers and offering logistical advantages such as extended shelf life and ...